1Berek JS, Schultes BC, Nicodemus CF. Biologic and immunologic therapies for ovarian cancer [J]. J Clin Oncol, 2003, 21 (10 Suppl): 168s-174s.
2Huang CT, Chang MC, Chen YL, et al. Insulin-like growth factors inhibit dendritic cell-mediated anti-tumor immunity through regulating ERK1/2 phosphorylation and p38 dephosphorylation [J]. Cancer Let-t, 2015, 359(1): 117-126.
3Chu CS, Boyer J, Schullery DS, et al. Phase HI randomized trial of dendritic cell vaccination with or without cyclophospharnide for consolidation therapy of advanced ovarian cancer in first or second remission[J]. Cancer Immunol Immunother, 2012, 61 (5): 629-641.
4Papaioatmou M, Mylonas I, Kast RE, et al. Disulfiram/copper causes redox-related proteotoxicity and concomitant heat shock response in ovarian cancer cells that is augmented by auranofin-rnediated thioredoxin inhibition[J]. Oncoscience, 2014, 1 ( 1): 21-29.
5Chiang CL, Kandalaft LE, Tanyi J, et al. A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity:from bench to bedside[J]. Clin Cancer Res, 2013, 19(17): 4801-4815.
6Rycaj K, Plummer JB, Yin B, et al. Cytotoxicity of human endogenous retrovirus K-specific T cells toward autologous ovarian cancer cells[J]. Clin Cancer Res, 2015, 21(2): 471-483.
7Zhu HL, Zou ZN, Lin PX, et al. Malignant transformation rate and p53, and pl 6 expression in teratomatous skin of ovarian mature cystic teratoma[J]. Asian Pac J Cancer Prey, 2015, 16(3): 1165-1168.
8Gritzapis AD, Sotiriadou NN, Papamichail M, et al. Generation of human tumor-specific CTLs in HLA-A2. 1-transgenic mice using unfractionated peptides from eluates of human primary breast and ovarian tumors [J]. Cancer Immunol Immunother, 2004, 53 (11): 1027-1040.
9Perillo A, Pierelli L, Battaglia A, et al. Administration of low-dose interleukin-2 plus G-CSF/EPO early after autologous PBSC transplantation: effects on immune recovery and NK activity in a prospective study in women with breast and ovarian cancer [J]. Bone Marrow Transplant, 2002, 30(9): 571-578.
10Oregovomab: anti-CA-125 monoclonal antibody B43.13-AltaRex, B43.13, MAb B43.13, monoclonal antibody B43.13 [J]. Drugs R D, 2006, 7(6): 379-383.
